Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world

AIDS and Behavior

Volumn 16, Issue 2, 2012, Pages 266-277

  Safren, Steven A ^a   Hendriksen, Ellen S ^a   Smeaton, Laura ^b   Celentano, David D ^c   Hosseinipour, Mina C ^d   Barnett, Ronald ^e   Guanira, Juan ^f   Flanigan, Timothy ^g   Kumarasamy, N ^h   Klingman, Karin ^e   Campbell, Thomas ⁱ  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f Investigaciones Medicas en Salud INMENSA   (Peru)

^g BROWN UNIVERSITY   (United States)

^h YRG CARE   (India)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Highly active antiretroviral therapy (HAART); HIV; Quality of life (QOL)

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AFRICA; ARTICLE; ASIA; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPING COUNTRY; ECONOMICS; FEMALE; HAITI; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; PHASE 4 CLINICAL TRIAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SOUTH AMERICA; TREATMENT OUTCOME; UNITED STATES; VIRUS LOAD;

ADULT; AFRICA; ANTI-HIV AGENTS; ASIA; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRIES; FEMALE; HAITI; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SOUTH AMERICA; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD;

EID: 84859716665     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-011-9947-5     Document Type: Article

References (30)

1. Brechtl JR, Breitbart W, Galietta M, Krivo S, Rosenfeld B. The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: impact on medical, palliative care, and quality of life outcomes. J Pain Symptom Manag. 2001;21: 41-51.
2. Bucciardini R, Wu AW, Floridia M, et al. Quality of life outcomes of combination zidovudine-didanosine-nevirapine and zidovudinedidanosine for antiretroviral-naive advanced HIVinfected patients. AIDS. 2000;14:2567-74.
3. Carrieri P, Spire B, Duran S, et al. Health-related quality of life after 1 year of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;32:38-47.
4. Nieuwkerk PT, Gisolf EH, Colebunders R, et al. Quality of life in asymptomatic and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. The Prometheus Study Group. AIDS. 2000;14:181-7.
5. Parsons TD, Braaten AJ, Hall CD, Robertson KR. Better quality of life with neuropsychological improvement on HAART. Health Qual Life Outcomes. 2006;4:11.
6. Saunders DS, Burgoyne RW. Evaluating health-related wellbeing outcomes among outpatient adults with human immunodeficiency virus infection in the HAART era. Int J STD AIDS. 2002;13: 683-90.
7. Wilson IB, Cleary PD. Linking clinical variables with healthrelated quality of life: a conceptual model of patient outcomes. JAMA. 1995;273:59-65.
8. U.S. Department of State. Action today, a foundation for tomorrow: the president's emergency plan for AIDS relief. Second annual report to Congress on PEPFAR. Department of State Publication 11316; Washington DC: Bureau of Global Affairs; 2006. 160 p.
9. Call SA, Klapow JC, Stewart KE, et al. Health-related quality of life and virologic outcomes in an HIV clinic. Qual Life Res. 2000;9:977-85.
10. Chan KS, Revicki DA. Changes in surrogate laboratory markers, clinical endpoints, and health-related quality of life in patients infected with the human immunodeficiency virus. Eval Health Prof. 1998;21:265-81.
11. Weinfurt KP, Willke RJ, Glick HA, Freimuth WW, Schulman KA. Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients. Med Care. 2000;38:404-10.
12. Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res. 1997;6: 481-93.
13. Wu AW. ACTG QOL 601-602 Health Survey Manual: Adult AIDS Clinical Trials Group. ACTG Outcomes Committee; 1999. Available from: https://www.fstrf.org/ apps/cfmx/apps/actg/html/QOLForms/manualql601-2799.pdf.
14. Wu AW, Huang IC, Gifford AL, Spritzer KL, Bozzette SA, Hays RD. Creating a crosswalk to estimate AIDS Clinical Trials Group quality of life scores in a nationally representative sample of persons in care for HIV in the United States. HIV Clin Trials. 2005;6:147-57.
15. Mrus JM, Williams PL, Tsevat J, Cohn SE, Wu AW. Gender differences in health-related quality of life in patients with HIV/AIDS. Qual Life Res. 2005;14:479-91.
16. Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr. 2007;46(5):547-54.
17. Crystal S, Fleishman JA, Hays RD, Shapiro MF, Bozzette SA. Physical and role functioning among persons with HIV: results from a nationally representative survey. Med Care. 2003;38: 1210-23.
18. Department of Health and Human Services (DHHS). Code of Federal Regulations, Title 45 Public Welfare, Part 46 Protection of Human Subjects. Department of Health and Human Services; 2009. Available from: http://www.hhs.gov/ohrp/policy/ohrpregul ations.pdf.
19. Wu AW, Hays RD, Kelly S, et al. Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS. Qual Life Res. 1997;6:531-54.
20. Davis AR, Ware JE. Measuring health perceptions in the Health Insurance Experiment. Santa Monica: The RAND Corporation (publication No. R-2711-HHS); 1981.
21. Stewart AL, Ware JE. Measuring functioning and well-being: The Medical Outcomes Study approach. Durham: Duke University Press; 1992.
22. Ware JE. SF-36 Health Survey: Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center; 1993.
23. Stewart AL, Hays RD, Ware JE Jr. The MOS short-form general health survey: reliability and validity in a patient population. Med Care. 1988;26:724-35.
24. Veit CT, Ware JE. The structure of psychological distress and well-being in general populations. J Consult Clin Psychol. 1983;51:730-42.
25. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS. 2001;15(17):2251-7.
26. Siegfried N, Uthman OA, Rutherford GW. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults. Cochrane Database Syst Rev. 2010;(3): CD008272.
27. Scott-Lenox JA, Wu AW, Boyer G, Ware JE. Reliability and validity of French, German, Italian, Dutch, and UK English translations of the Medical Outcomes Study HIV Health Survey. Med Care. 1999;37(9):908-25.
28. Ichikawa M, Natpratan C. Quality of life among people living with HIV/AIDS in northern Thailand: MOS-HIV Health Survey. Qual Life Res. 2004;13(3):601-10.
29. Lau JT, Tsui HY, Patrick LC, Rita CW, Molassiotis A. Validation of a Chinese version of the Medical Outcomes Study HIV Health Survey (MOS-HIV) among Chinese people living with HIV/AIDS in Hong Kong. Qual Life Res. 2006;15(6):1079-89.
30. Stasinopoulou PG, Tzavara C, Dimitrakaki C, Georgiou O, Baraboutis IG, Skoutelis A, Papastamipoulos V, Tountas Y. Reliability and validity of the Greek translation of the MOS-HIV health survey in HIV-infected individuals. Qual Life Res. 2010 Jan 12; (Epub ahead of print).